Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients and its property management business. The company has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region, and a licensing and collaboration agreement with Guangzhou Fermion Technology Co., Ltd. to develop FZ002-037, an oral SSTR4 agonist for pain treatment. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.